IGBA Comments to the 13 March 2024 Proposal for negotiating text of the Pandemic Agreement (April 2024)
As the international representative organization of the generic and biosimilar medicines industry, IGBA joins the WHO and Member States in reaffirming the importance of multisectoral collaboration to safeguard human health and build stronger, more resilient health systems. In an open letter concerning the International Negotiating Body (INB) negotiations of the Pandemic Agreement, dated January 2024, our association expressed it support to having an international legal instrument for the achievement of access to cost-effective, quality-assured, safe, and effective medicines. With the aim to take part of the public debate, in the framework of the 9th meeting of the INB, we would respectfully like to present a new round of observations.
